TABLE 3.
Baseline characteristics for patients with prior sinus surgery by time since last surgery
| Characteristic |
<3 years (n = 136) |
≥3 and <5 years (n = 81) |
≥5 and <10 years (n = 133) |
≥10 years (n = 108) |
Overall p a |
|---|---|---|---|---|---|
| Age (years) | 46.35 (12.51) | 50.38 (12.49) | 53.21 (12.13) | 56.19 (11.17) | <0.001 |
| Male, n % | 87 (64.0) | 48 (59.3) | 74 (55.6) | 59 (54.6) | 0.42 |
| BMI (kg/m2) | 27.64 (5.92) | 26.81 (4.77) | 28.04 (4.61) | 27.68 (5.65) | 0.41 |
| Time since first diagnosis of NP (years) | 8.56 (7.11) | 11.66 (8.11) | 15.32 (7.99) | 22.01 (9.88) | <0.001 |
| Age at onset of NP (years) | 37.82 (13.17) | 38.78 (13.93) | 38.08 (13.13) | 34.21 (12.40) | 0.10 |
| Asthma/NSAID‐ERD from medical history, n (%) | 87 (64.0) | 64 (79.0) | 101 (75.9) | 69 (63.9) | 0.02 |
| SCS use within 2 years, n (%) | 89 (65.4) | 51 (63.0) | 79 (59.4) | 72 (66.7) | 0.64 |
| Type of last surgery, n (%) | |||||
| FESS | 72 (52.9) | 47 (58.0) | 75 (56.4) | 54 (50.0) | |
| Polypectomy | 64 (47.1) | 34 (42.0) | 58 (43.6) | 54 (50.0) | |
| Number of prior sinus surgeries category, n (%) | 0.03 | ||||
| 1 surgery | 70 (51.5) | 41 (50.6) | 70 (52.6) | 72 (66.7) | |
| 2 surgeries | 24 (17.6) | 19 (23.5) | 28 (21.1) | 23 (21.3) | |
| ≥3 surgeries | 42 (30.9) | 21 (25.9) | 35 (26.3) | 13 (12.0) | |
| Assessment scores, mean (SD) | |||||
| NPS (0−8) | 5.41 (1.17) | 5.75 (1.18) | 6.05 (1.27) | 6.27 (1.27) | <0.001 |
| NC score (0−3) | 2.41 (0.53) | 2.37 (0.65) | 2.50 (0.55) | 2.46 (0.56) | 0.59 |
| LMK score (0−24) | 19.96 (3.78) | 19.75 (4.02) | 19.05 (3.76) | 17.38 (3.96) | <0.001 |
| UPSIT score (0−40) | 13.50 (7.70) | 12.20 (7.13) | 12.01 (7.14) | 13.34 (8.00) | 0.48 |
| Loss of smell score (0−3) | 2.80 (0.46) | 2.80 (0.44) | 2.84 (0.44) | 2.69 (0.71) | 0.36 |
| SNOT‐22 total score (0−110) | 51.56 (20.05) | 52.09 (21.47) | 52.62 (19.21) | 49.82 (20.56) | 0.80 |
| VAS for EQ‐5D (0−100) | 65.64 (19.84) | 69.45 (17.40) | 62.60 (20.41) | 65.61 (18.35) | 0.15 |
| Biomarkers, mean (SD) | |||||
| Blood eosinophils (1 × 109/L) | 0.45 (0.30) | 0.56 (0.47) | 0.45 (0.31) | 0.45 (0.39) | 0.31 |
| Total IgE (IU/mL) | 225.88 (271.55) | 241.24 (327.49) | 219.84 (342.49) | 202.69 (358.01) | 0.37 |
| Periostin (ng/mL) | 125.89 (60.60) | 127.23 (53.83) | 107.45 (44.52) | 107.89 (45.95) | 0.002 |
| TARC (pg/mL) | 373.04 (264.40) | 389.53 (277.67) | 308.49 (157.15) | 389.50 (314.23) | 0.17 |
Chi‐square test for qualitative parameters, Kruskal‐Wallis test for quantitative parameters; to compare if there was a difference between at least 2 subgroups among patients with < 3, ≥3 to <5, ≥5 to <10, and ≥10 years since last sinus surgery.
BMI = body mass index; EQ‐5D = European Quality of Life‐five Dimensions; FESS = functional endoscopic sinus surgery; IgE = immunoglobulin E; LMK = Lund‐Mackay; NC = nasal congestion; NP = nasal polyposis; NPS = nasal polyp score; NSAID‐ERD = nonsteroidal anti‐inflammatory drug–exacerbated respiratory tract disease; SCS = systemic corticosteroid; SD = standard deviation; SNOT‐22 = 22‐item Sino‐Nasal Outcome Test; TARC = thymus and activation‐regulated chemokine; UPSIT = University of Pennsylvania Smell Identification Test; VAS = visual analogue scale.